Keros Therapeutics, Inc.KROSNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+19.4%
5Y CAGR+30.9%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+19.4%/yr
vs +104.3%/yr prior
5Y CAGR
+30.9%/yr
Recent deceleration
Acceleration
-84.9pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
3.8x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$46.85M+15.0%
2024$40.75M+17.0%
2023$34.83M+26.6%
2022$27.52M+29.0%
2021$21.33M+75.0%
2020$12.19M+282.9%
2019$3.18M+101.5%
2018$1.58M-